| Date | Time | Source | Headline | Symbol | Company |
| 03/02/2022 | 6:20AM | TipRanks | AbbVie Strengthens Neuroscience Portfolio with Syndesi Acquisition | NYSE:ABBV | AbbVie Inc |
| 03/01/2022 | 6:44PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:ABBV | AbbVie Inc |
| 03/01/2022 | 6:44PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:ABBV | AbbVie Inc |
| 03/01/2022 | 6:44PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:ABBV | AbbVie Inc |
| 03/01/2022 | 6:32PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:ABBV | AbbVie Inc |
| 03/01/2022 | 6:32PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:ABBV | AbbVie Inc |
| 03/01/2022 | 6:31PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:ABBV | AbbVie Inc |
| 03/01/2022 | 6:31PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:ABBV | AbbVie Inc |
| 03/01/2022 | 8:58AM | Dow Jones News | AbbVie Buys Syndesi Therapeutics for Up to $1 Billion | NYSE:ABBV | AbbVie Inc |
| 03/01/2022 | 8:30AM | PR Newswire (US) | AbbVie to Present at the Cowen 42nd Annual Health Care Conference | NYSE:ABBV | AbbVie Inc |
| 03/01/2022 | 8:00AM | PR Newswire (US) | AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio | NYSE:ABBV | AbbVie Inc |
| 02/28/2022 | 4:15PM | PR Newswire (US) | AbbVie Provides Update Regarding SKYRIZI® (risankizumab-rzaa) for the Treatment of Moderate to Severe Crohn's Disease in the U.S. | NYSE:ABBV | AbbVie Inc |
| 02/28/2022 | 8:00AM | PR Newswire (US) | AbbVie Seeks New Indication for IMBRUVICA® (ibrutinib) in Pediatric Patients with Chronic Graft Versus Host Disease (cGVHD) | NYSE:ABBV | AbbVie Inc |
| 02/24/2022 | 11:22AM | PR Newswire (US) | Allergan, an AbbVie Company, to Present Data from its Leading Portfolio of Eye Care Treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting | NYSE:ABBV | AbbVie Inc |
| 02/24/2022 | 8:00AM | PR Newswire (US) | Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ®) Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease | NYSE:ABBV | AbbVie Inc |
| 02/24/2022 | 7:00AM | PR Newswire (Canada) | AbbVie annonce le remboursement provincial, en Alberta, en Saskatchewan, en Colombie-Britannique et au Manitoba, de VENCLEXTA® (vénétoclax) en association avec l'obinutuzumab pour le traitement des patients atteints de leucémie lymphoïde chronique (LL | NYSE:ABBV | AbbVie Inc |
| 02/24/2022 | 7:00AM | PR Newswire (Canada) | AbbVie Announces Provincial Reimbursement for VENCLEXTA® (venetoclax) with Obinutuzumab for Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) in Alberta, Saskatchewan, British Columbia, and Manitoba | NYSE:ABBV | AbbVie Inc |
| 02/22/2022 | 5:44PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:ABBV | AbbVie Inc |
| 02/22/2022 | 5:43PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:ABBV | AbbVie Inc |
| 02/22/2022 | 5:43PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:ABBV | AbbVie Inc |
| 02/22/2022 | 5:43PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:ABBV | AbbVie Inc |
| 02/22/2022 | 5:41PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:ABBV | AbbVie Inc |
| 02/22/2022 | 5:41PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:ABBV | AbbVie Inc |
| 02/22/2022 | 5:36PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:ABBV | AbbVie Inc |
| 02/22/2022 | 5:35PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:ABBV | AbbVie Inc |
| 02/22/2022 | 5:04PM | Edgar (US Regulatory) | Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) | NYSE:ABBV | AbbVie Inc |
| 02/22/2022 | 8:15AM | PR Newswire (US) | AbbVie Submits Supplemental New Drug Application to U.S. FDA for cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder | NYSE:ABBV | AbbVie Inc |
| 02/18/2022 | 12:43PM | Edgar (US Regulatory) | Annual Report (10-k) | NYSE:ABBV | AbbVie Inc |
| 02/17/2022 | 11:33AM | PR Newswire (US) | AbbVie Declares Quarterly Dividend | NYSE:ABBV | AbbVie Inc |
| 02/15/2022 | 7:01AM | PR Newswire (Canada) | AbbVie and the University of Toronto Establish Endowed Chair in Ethnodermatology | NYSE:ABBV | AbbVie Inc |